4. You mentioned on the call that Caliber was the only US facility able to mass produce a vaccine such as Ebola in tobacco plants were it needed. Could you elaborate on this? "That is my opinion based on the following assumptions: After the success of the Fraunhofer iBioLaunch-based pilot plant, under license from iBio, in rapid production of influenza antigens as part of the DARPA "Accelerated Manufacturing of Pharmaceuticals" program, the Department of Defense awarded three companies contracts to build or expand capacity for rapid-response plant-made production of biopharmaceuticals. One was to Medicago which is now owned by Mitsubishi and devoted primarily to producing VLP-type vaccines in plants, another was to Kentucky Bioprocessing (KBP) which is now owned by RJR and produces small quantities of a variety of proteins for phase 1 clinical trials along with processing of tobacco for non-pharmaceutical purposes, and the third was to the predecessor/parent company of Caliber, G-Con LLC, supported by a Letter of Intent, Research License, and Material Transfer Agreement from iBio. For the past three plus years, Caliber has worked almost entirely on antibodies and has full-scale, pilot, and laboratory capacity all capable of operating to U.S. cGMP standards. The facility is currently capable of growing 2.2 million plants at once and without expansion can produce at least 100 kilograms of purified pharmaceutical grade recombinant antibody in a year. The number of plants grown can be doubled without new construction by adding lights and growth racks. Both the Medicago and the KBP facilities would need significant downstream reconfiguration to switch to large scale antibody production, but Caliber is ready to go now."
According to Mr. Erwin, "iBio has exclusive rights to technology directly relevant to increasing yields and accelerating production of anti-Ebola antibodies and vaccines, issued U.S. patents that cover important processes needed for production of such products in plants, and a longstanding and productive relationship with Caliber Biotherapeutics. We expect to perform an important role in the emergency response to the current outbreak and to see our technology and products used in other important human healthcare applications in the future."
IBIO is breaking out today having cleared major resistance at 81c. Given the substantial moves in its peers that have no relationship to ZMapp IBIO could be setting up for a very large move in its stock price in the near term.
2. Does Caliber's plant-based vaccine process use/require Ibio technology? If so does Ibio receive payments/royalties on the use of this technology?
"The agreement provides for iBio to receive license and milestone fees for development of product targets selected by Caliber and royalties on products sales and other revenues. Detailed financial terms have not been disclosed have not been disclosed."
3. If Caliber wins the Ebola contract would Ibio be in a position to confirm its use in a press release?
"Technology used to produce the ZMapp antibodies in plants is covered by issued U.S. patents owned by iBio, and iBio also has additional proprietary technology that can be applied to increase the antibody yields over current levels. However, we cannot speculate on contracts that might or might not be awarded."
Also mentioned in Forbes.
Makes protein for Zmapp $20+